NCT07650058 Postprandial Effects of Fresh Mango as a Table Sugar Replacement in High-Sugar Breakfasts.
| NCT ID | NCT07650058 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ball State University |
| Condition | Healthy Participants |
| Study Type | INTERVENTIONAL |
| Enrollment | 35 participants |
| Start Date | 2026-02-01 |
| Primary Completion | 2026-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 35 participants in total. It began in 2026-02-01 with a primary completion date of 2026-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Systemic inflammation and intestinal hyperpermeability (disruption of the gut barrier which allows nutrient molecules and bacteria to enter the bloodstream) are triggered by consumption of high-sugar meals and are linked to future development of cardiovascular disease (CVD). Previous research indicates that fresh mangos have properties that have positive effects on the intestinal barrier and local gut inflammation. The investigators want to understand if replacing table sugar (sucrose) with sugar from fresh mango (which also contains fiber and plant bioactives) will lead to decreased inflammatory and permeability biomarkers after eating a high-sugar breakfast. The investigators will compare the postprandial (post meal) levels of inflammatory (IL-6) and permeability (LPS, lipid binding protein (LBP), and soluble CD14) biomarkers in blood from participants who have consumed a meal sweetened with either sucrose or fresh mango.
Eligibility Criteria
Inclusion Criteria: * 18 - 45 years. * Body mass index between 18.5-35.0 kg/m2 * Not pregnant or expecting to become pregnant (females only) * Not postmenopausal (females only). * No known chronic medical conditions (e.g., type 2 diabetes, cardiovascular disease, inflammatory diseases, etc.) * No history of using tobacco/illicit drugs * No history of using glucose-lowering medications/supplements. * No history of using prescribed anti-inflammatory medications * Does not use over-the-counter anti-inflammatory medications ≥2x/week * Does not have a pacemaker. * No relevant food allergies/intolerances * Able to lay supine for at least ten minutes. Exclusion Criteria: * Not between the ages of 18-45 * Body mass index \< 18.5 kg/m2 or \>35.0 kg/m2 * Pregnant (females only) * Postmenopausal status (females only). * Been diagnosed with a chronic medical conditions (e.g., type 2 diabetes, cardiovascular disease, inflammatory diseases, etc.) * Uses tobacco products or any illicit drugs. * Uses glucose-lowering drugs/supplements. * Regularly takes anti-inflammatory drugs (more than 2x week). * Have a pacemaker. * Allergic to mango, wheat, gluten, and/or milk. * Unable to lay in supine position in the dark for at least ten minutes.
Contact & Investigator
Bryant Keirns, PhD
PRINCIPAL INVESTIGATOR
Ball State University
Frequently Asked Questions
Who can join the NCT07650058 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 45 Years, studying Healthy Participants. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07650058 currently recruiting?
Yes, NCT07650058 is actively recruiting participants. Contact the research team at bryant.keirns@bsu.edu for enrollment information.
Where is the NCT07650058 trial being conducted?
This trial is being conducted at Muncie, United States.
Who is sponsoring the NCT07650058 clinical trial?
NCT07650058 is sponsored by Ball State University. The principal investigator is Bryant Keirns, PhD at Ball State University. The trial plans to enroll 35 participants.